The Realities Reshaping Phase I Trials For Sponsors

Phase I clinical trials are no longer defined solely by dose escalation and safety assessments in healthy volunteers. As therapies for cancer, rare diseases, immune disorders, and other complex conditions become more targeted, early-stage studies increasingly enroll patients, incorporate efficacy endpoints, and leverage adaptive designs to inform development decisions sooner. This evolution is changing how sponsors approach protocol design, regulatory strategy, and ethics review.

Modern Phase I programs often include expansion cohorts, built-in decision points, and flexible study structures that can accelerate development while reducing unnecessary amendments. Success depends on anticipating operational and regulatory complexities early, from protocol development and IRB review to IND timing and long-term study planning. Sponsors that understand these shifts can better position programs for efficient execution while maintaining scientific and regulatory rigor.

Read the full article to explore how evolving trial designs are reshaping sponsor planning and what it takes to navigate today’s increasingly complex Phase I landscape.